

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 70926

Title: Surgery for hepatocellular carcinoma with tumor thrombosis in inferior vena cava:

A case report

Reviewer's code: 03479093 Position: Editorial Board

Academic degree: FACS, FEBS, MD, PhD

Professional title: Director, Full Professor, Senior Lecturer, Senior Researcher, Surgeon

Reviewer's Country/Territory: Saudi Arabia

Author's Country/Territory: China

Manuscript submission date: 2021-08-19

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-08-22 12:41

Reviewer performed review: 2021-08-26 12:44

Review time: 4 Days

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y]Yes []No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

This is study represents a promising therapy option but only for a very selected patient collective. Advanced HCC with vascular invasion is mostly associated with liver cirrhosis, in which major resction is contraindicated. So tis patient was lucky to be young, in a cardiovascular excellent condition and without cirrhosis. We can add this interdisciplinary approach to some selected cases in the future of treating advanced HCC.\However there is one additional therapeutic option that can be considered which would be TARE (Transarterial radioembolization) known to treat advanced HCC with vascular invaion such as portal vein tumor thrombosis. I would suggest to include publications comparing TARE to TACE and or szstemic therapy. Because in unfiiter patienst surgery and thrombectomy is not an option and TARE should be discussed equally or superior to the alternative treatments offered in this report. In summary the manuscript should be revised and resubmitted including a comparsion to TARE as to the alternatives mentioned in the discussion.